Drug Profile
Research programme: cancer and neurology therapeutics - Zenotech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Zenotech Laboratories
- Class Antigens; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in India
- 08 Oct 2007 Preclinical trials in Cancer in India (unspecified route)